Advertisement

Doklady Biochemistry and Biophysics

, Volume 483, Issue 1, pp 313–315 | Cite as

Polyarginine Peptides As a New Class of Ligands of Nicotinic Acetylcholine Receptors

  • E. V. KryukovaEmail author
  • I. A. Ivanov
  • D. S. Lebedev
  • E. N. Spirova
  • D. A. Senko
  • N. S. Egorova
  • I. E. Kasheverov
  • V. I. Tsetlin
Biochemistry, Biophysics, and Molecular Biology
  • 22 Downloads

Abstract

Arginine-containing peptides R3, R8, and R16 were obtained by solid-phase peptide synthesis, and their binding to nicotinic acetylcholine receptors (nAChRs) of muscle and neuronal (α7) types was studied by competitive radioligand assay with the use of 125I-α-bungarotoxin. The resulting peptides exhibited a significantly greater binding activity with respect to the muscle-type nAChRs than to the α7 receptor. Thus, we have discovered a new class of nAChR ligands. The affinity of the synthesized oligoarginines for nAChR depended on the number of amino acid residues in the chain. The highest affinity was exhibited by the R16 peptide, which contained 16 arginine residues.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lindstrom, J., Anand, R., Peng, X., Gerzanich, V., Wang, F., and Li, Y., Ann. N.Y. Acad. Sci., 1995, vol. 757, pp. 100–116.CrossRefGoogle Scholar
  2. 2.
    Wang, H., Yu, M., Ochani, M., Amella, C.A., Tanovic, M., Susarla, S., Li, J.H., Wang, H., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C.J., and Tracey, K.J., Nature, 2003, vol. 421, no. 6921, pp. 384–388.CrossRefGoogle Scholar
  3. 3.
    Kawashima, K., Fujii, T., Moriwaki, Y., Misawa, H., and Horiguchi, K., Int. Immunopharmacol., 2015, vol. 29, no. 1, pp. 127–134.CrossRefGoogle Scholar
  4. 4.
    Spindel, E.R., Curr. Pharm. Des., 2016, vol. 22, no. 14, pp. 2152–2159.CrossRefGoogle Scholar
  5. 5.
    Tsetlin, V.I. and Hucho, F., FEBS Lett., 2004, vol. 557, pp. 9–13.CrossRefGoogle Scholar
  6. 6.
    Dutertre, S., Nicke, A., and Tsetlin, V.I., Neuropharmacology, 2017, vol. 127, pp. 196–223.CrossRefGoogle Scholar
  7. 7.
    Azam, L. and McIntosh, J.M., Acta Pharmacol. Sin., 2009, vol. 30, pp. 771–783.CrossRefGoogle Scholar
  8. 8.
    Christensen, S.B., Hone, A.J., Roux, I., Kniazeff, J., Pin, J.P., Upert, G., Servent, D., Glowatzki, E., and McIntosh, J.M., Front. Cell. Neurosci., 2017, vol. 11, p. 219.CrossRefGoogle Scholar
  9. 9.
    Luo, S., Zhangsun, D., Harvey, P.J., Kaas, Q., Wu, Y., Zhu, X., Hu, Y., Li, X., Tsetlin, V.I., Christensen, S., Romero, H.K., McIntyr, M., Dowell, C., Baxter, J.C., Elmslie, K.S., Craik, D.J., and McIntosh, J.M., Proc. Natl. Acad. Sci. U. S. A., 2015, vol. 112, pp. 4026–4035.CrossRefGoogle Scholar
  10. 10.
    Utkin, Yu.N., Weise, Ch., Hoang, N.A., Kasheverov, I.E., Starkov, V.G., and Tsetlin, V.I., Dokl. Biochem. Biophys., 2012, vol. 442, pp. 33–35.CrossRefGoogle Scholar
  11. 11.
    Kasheverov, I.E., Zhmak, M.N., Vulfius, C.A., Gorbacheva, E.V., Mordvintsev, D.Y., Utkin, Y.N., van Elk, R., Smit, A.B., and Tsetlin, V.I., FEBS J., 2006, vol. 273, pp. 4470–4481.CrossRefGoogle Scholar
  12. 12.
    Kasheverov, I.E., Chugunov, A.O., Kudryavtsev, D.S., Ivanov, I.A., Zhmak, M.N., Shelukhina, I.V., Spirova, E.N., Tabakmakher, V.M., Zelepuga, E.A., Efremov, R.G., and Tsetlin, V.I., Sci. Rep., 2016, vol. 6, no. 36848.Google Scholar

Copyright information

© Pleiades Publishing, Inc. 2018

Authors and Affiliations

  • E. V. Kryukova
    • 1
    Email author
  • I. A. Ivanov
    • 1
  • D. S. Lebedev
    • 1
  • E. N. Spirova
    • 1
  • D. A. Senko
    • 1
  • N. S. Egorova
    • 1
  • I. E. Kasheverov
    • 1
    • 2
  • V. I. Tsetlin
    • 1
  1. 1.Shemyakin–Ovchinnikov Institute of Bioorganic ChemistryRussian Academy of SciencesMoscowRussia
  2. 2.Sechenov First Moscow State Medical UniversityMinistry of Healthcare of the Russian FederationMoscowRussia

Personalised recommendations